Actavis’ Record-Breaking Quarterly Sales Show Success Of Merger Strategy
This article was originally published in The Pink Sheet Daily
Executive Summary
Strong quarter for generic Mycardis, Lidoderm and Cymbalta spurs 36% increase in pharma product sales, while businesses inherited from Warner Chilcott lead to exponential growth in North American branded product revenue. Firm is getting ready for integration of Forest around mid-year.
You may also be interested in...
Watson Begins Anew As Actavis, Focuses On Organic Growth
The traditionally generic-heavy company now has an expanded global presence and a growing branded business to go with its new name.
iPLEDGE REMS: FDA Panel To Consider Changing Pregnancy Testing, Counseling Requirements
Advisory committee to discuss proposed changes to isotretinoin REMS to minimize burden and treatment delays while preventing risk of fetal exposure. Agency recommends against at-home pregnancy tests.
Pink Sheet Podcast: Moderna CEO On Capitol Hill, Xtandi March-In Rights, Tofersen Adcomm In ALS
Pink Sheet reporter and editors discuss Moderna CEO’s Stéphane Bancel’s defense of his company and COVID-19 vaccine pricing at the Senate Health, Education, Labor and Pensions Committee, the NIH denying a petition to use government march-in rights for Xtandi, and Tofersen receiving a positive US FDA advisory committee recommendation for use in ALS.